🔗 Share this article

As the US continues making historic changes to its vaccine schedules, a particular individual has surfaced unexpectedly: Dr. Tracy Beth Høeg, a Danish American sports physician and epidemiologist who first made her name by expressing skepticism about coronavirus vaccines in the pandemic and has concentrated on possible fatalities following COVID-19 vaccination in her brief position at the FDA.

Planned Shifts to Pediatric Immunization Program

Health officials planned to reveal major changes to the childhood vaccination calendar earlier this month, synchronizing the US with Denmark’s national calendar, sources say – a substantial departure that would place the US out of alignment with many the global community with insufficient data for benefit. The announcement has been pushed back until the new year.

Instead of the director of the vaccine center, Høeg is set to speak at the event. She was just designated acting director of the FDA’s drug evaluation center, the fifth person to run the division this calendar year.

Consolidating Power at the Agency

The acting appointment could signify a tighter collaboration between the pharmaceutical and vaccine divisions as Høeg and Prasad strengthen their influence at the FDA – and it points to a greater focus upon reevaluating previously authorized immunizations at the FDA.

Høeg has repeatedly called for ending certain childhood vaccine recommendations in the US so as to align more like the Danish model, a society with universal health coverage and a citizenry approximately the population of Wisconsin’s.

To date statements, she has kept her attention on immunizations – traditionally the purview of Prasad, chief of the FDA’s vaccine center – as opposed to pharmaceutical oversight.

Doubts Over Qualifications

Dr. Høeg has little discernible experience in drug development, approval processes or management, which has been standard for past leaders of the Center for Biologics Evaluation and Research. She has been employed at the FDA as a senior adviser to the FDA chief and the vaccine center since spring.

“She doesn’t seem to have the requisite experience” for overseeing the pharmaceutical oversight division, said a neurologist and psychiatrist. “She has not conducted a randomized controlled trial. She has no expertise in leading a sizeable institution. She lacks background in industry regulation.”

Former commissioners of CBER would “understand regulatory frameworks and the research of medication creation”, said a former acting FDA commissioner. “Clearly, she doesn’t have the type of experience that prior appointees who led CBER have had.”

This division has an enormous range of responsibilities at the FDA, Woodcock stated.

“Everybody just pays attention on the innovative therapies, but the off-patent medication office authorizes numerous generic drugs. There is also a biosimilars division, OTC medication office and other areas, and each of these have to be managed,” she noted. “The area you overlook, that is the part that I always told people is going to come back to haunt you.”

Furthermore, a major management component to the job, which supervises in excess of 5,000 staff members. “It’s a huge management job, if you perform it correctly,” Woodcock concluded.

Response and Contentious Policies

Regarding questions about Høeg’s credentials and whether this selection indicates greater collaboration among regulatory chiefs on vaccines, a representative stated that the “questions rely on incorrect assumptions”.

“Her experience is consistent with the responsibilities of her role,” the official said, pointing to the months Høeg spent advising the FDA commissioner on “pharmaceutical safety and approval science, including computerized risk analysis and vaccine surveillance”.

As the temporary head, Dr. Høeg takes over the commissioner’s controversial fast-track approval initiative, a disputed one-day therapy clearance system that reportedly concerned her former heads. “By what process are these drugs being selected for this voucher program? Who takes the choices?” Howard questioned. “There is a lot of confidentiality happening at the agency right now.”

Overall, he said, “the FDA appears to be shifting towards less stringent oversight of pharmaceuticals, aside from vaccines.”

Established Past Work on Immunizations

Concerning vaccines, Dr. Høeg has a more documented, if concerning, past, critics said. She published a analysis using unconfirmed public submissions to determine the frequency of myocarditis after COVID-19 vaccination. She advised the Florida chief medical officer Joseph Ladapo, who reportedly have modified findings to suggest Covid vaccines are more dangerous than they are.

Among her “desired changes” for the new government included changing guidelines for novel immunizations and ending “non-essential” immunizations, she said post-election on a online show. At the agency, Dr. Høeg has reportedly suggested excluding young men from receiving Covid vaccines.

“She’s an complete ideologue who starts off with her preconceived notions and reverse-engineers to accommodate the science in a very deceptive, untruthful fashion,” Dr. Howard said.

Gaining Influence and a “Push for Payback”

Dr. Høeg became part of other dissenters, {like|